Search form


Press Releases

Axcan Announces Conference Call and Web Cast for First Quarter of Fiscal 2005 Results

Feb 07, 2005 - 12:00 ET

MONT SAINT-HILAIRE, Quebec, Feb. 7 - Axcan Pharma Inc.
("Axcan" or the "Company") today announced that it will report financial
results for the first quarter of fiscal 2005 ended Dec. 31, 2004, on Monday,
February 14, 2005.
Axcan will host a conference call at 4:30 P.M. ET, on February 14, 2005.
Interested parties may also access the conference call by web cast at .
The telephone numbers to access the conference call are (800) 814-4941
(Canada and United States) or (416) 850-1243 (international). A replay of the
call will be available until February 21, 2005. The telephone number to access
the replay of the call is (416) 640-1917 code: 21112528.

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".


    "Safe Harbor" statement under the Private Securities Litigation Reform
    Act of 1995.
    To the extent any statements made in this release contain information
    that is not historical, these statements are essentially forward looking
    and are subject to risks and uncertainties, including the difficulty of
    predicting FDA and other regulatory approvals, acceptance and demand for
    new pharmaceutical products, the impact of competitive products and
    pricing, new product development and launch, reliance on key strategic
    alliances, availability of raw materials, the regulatory environment,
    fluctuations in operating results and other risks detailed from time to
    time in the Company's filings with the Securities and Exchange Commission
    and the Canadian Multijurisdictional Disclosure System.


Julie M. Thibodeau, Manager, Investor 
Relations, Axcan Pharma Inc., (450) 467-5138, ext. 2062; ; 
Source: Axcan Pharma Inc.